<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Response of select subtypes of ichthyosis to treatment with topical keratolytics, topical retinoids, and systemic retinoids</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Response of select subtypes of ichthyosis to treatment with topical keratolytics, topical retinoids, and systemic retinoids</h1>
<div class="graphic"><div class="figure"><div class="ttl">Response of select subtypes of ichthyosis to treatment with topical keratolytics, topical retinoids, and systemic retinoids</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="12%"></colgroup><colgroup width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Classification</td> <td class="subtitle1" colspan="2">Disease</td> <td class="subtitle1">Response to keratolytic agents*</td> <td class="subtitle1">Response to topical retinoids</td> <td class="subtitle1">Response to systemic retinoids</td> <td class="subtitle1">Comments</td> </tr> <tr> <td rowspan="9">Selected nonsyndromic ichthyoses</td> <td colspan="2">Ichthyosis vulgaris</td> <td class="centered">+</td> <td class="centered">+</td> <td class="centered">Not recommended</td> <td> <ul> <li>May tolerate keratolytic agents poorly.</li> </ul> </td> </tr> <tr> <td colspan="2">Recessive X-linked ichthyosis (steroid sulfatase deficiency)</td> <td class="centered" rowspan="2">++</td> <td class="centered" rowspan="2">++</td> <td class="centered" rowspan="2">++</td> <td rowspan="2"> <ul> <li>Retention of scale; responds well to peeling agents.</li> <li>Response to topical retinoids is typically superior to that of keratolytic agents.</li> </ul> </td> </tr> <tr> <td colspan="2">Autosomal recessive sulfatase deficiency</td> </tr> <tr> <td rowspan="3">Keratinopathic ichthyosis</td> <td>Epidermolytic ichthyosis (formerly called ichthyosis bullosa of Brocq or epidermolytic hyperkeratosis)</td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">++</td> <td rowspan="2"> <ul> <li>Helpful for some patients, but skin irritation and tendency to blister are limiting factors of keratolytic and retinoid use.</li> <li>Palmoplantar thickening is particularly problematic with <em>KRT1</em> (versus <em>KRT10</em>) epidermolytic ichthyosis variants.</li> <li>Superficial epidermolytic ichthyosis tends to be less severe than epidermolytic ichthyosis.</li> </ul> </td> </tr> <tr> <td>Superficial epidermolytic ichthyosis (formerly called ichthyosis bullosa of Siemens)</td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">+</td> </tr> <tr> <td>Ichthyosis with confetti</td> <td class="centered">Not recommended</td> <td class="centered">+</td> <td class="centered">++</td> <td> <ul> <li>Anecdotally, topical tazarotene is more beneficial and better tolerated than tretinoin.</li> </ul> </td> </tr> <tr> <td rowspan="3">Autosomal recessive congenital ichthyosis</td> <td>Harlequin ichthyosis</td> <td class="centered">Not recommended</td> <td class="centered">+</td> <td class="centered">++</td> <td> <ul> <li>Topical tazarotene is helpful for loosening skin of hands, ears, periorificial areas.</li> <li>Systemic retinoids are a good option in the perinatal period and in infancy, although their use is not required in many cases; need after first months should be individualized, but many patients do well without retinoids.</li> </ul> </td> </tr> <tr> <td>Congenital ichthyosiform erythroderma</td> <td class="centered">++</td> <td class="centered">+</td> <td class="centered">Not recommended</td> <td> <ul> <li>Retinoids often poorly tolerated but topical retinoids may be considered for selected areas of skin thickening.</li> <li>Patients may respond to Th17 pathway inhibition.</li> </ul> </td> </tr> <tr> <td>Lamellar ichthyosis</td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">++</td> <td> <ul> <li>Excellent response to retinoids.</li> <li>Use of topical versus systemic retinoid depends on severity.</li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td rowspan="2">Selected syndromic ichthyoses</td> <td colspan="2">Netherton syndrome<sup>¶</sup></td> <td class="centered">Not recommended</td> <td class="centered">Not recommended</td> <td class="centered">Not recommended</td> <td> <ul> <li>Poor tolerability of keratolytic agents and retinoids.</li> <li>Broad treatment with IVIG has been successfully used in 1 patient<sup>[1-3]</sup>. More targeted therapy with various biologics have reduced erythema and scaling: secukinumab (IL-17 inhibitor)<sup>[4]</sup>, ustekinumab (IL-12/IL-23 inhibitor)<sup>[5]</sup>; less often dupilumab (IL-4 receptor inhibitor)<sup>[6,7]</sup>; infliximab (TNF inhibitor)<sup>[8,9]</sup> and omalizumab (targets IgE) with pulse steroids<sup>[10]</sup>.</li> <li>NBUVB therapy is a potential option<sup>[11,12]</sup>.</li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td colspan="2">Sjögren-Larsson syndrome</td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">++</td> <td> <ul> <li>Progressive neurologic issues often overshadow skin management.</li> </ul> </td> </tr> <tr> <td rowspan="4">Other disorders of differentiation</td> <td colspan="2">Erythrokeratodermias<sup>¶</sup></td> <td class="centered">Not recommended</td> <td class="centered">Not recommended</td> <td class="centered">++</td> <td> <ul> <li>Ustekinumab can reverse skin and heart disease progression of EKC syndrome<sup>[13,14]</sup>.</li> <li>Isotretinoin led to significant, near-complete resolution of skin symptoms in recessive progressive symmetric erythrokeratoderma<sup>[15]</sup>.</li> </ul> </td> </tr> <tr> <td colspan="2">SAM syndrome<sup>¶</sup></td> <td class="centered">+</td> <td class="centered">Not recommended</td> <td class="centered">Not recommended</td> <td> <ul> <li>May use keratolytic agents for palmoplantar keratoderma.</li> <li>Trial of secukinumab therapy led to dramatic improvement of skin manifestations in 1 case but improved weight gain and reduced infection in a second<sup>[16]</sup>.</li> </ul> </td> </tr> <tr> <td colspan="2">Darier disease</td> <td class="centered">++</td> <td class="centered">Not recommended</td> <td class="centered">++</td> <td> <ul> <li>Retinoids are treatment of choice, but topical corticosteroids may help reduce inflammation.</li> <li>Infection control (<em>Staphylococcus aureus</em>, fungi, herpes simplex) is important.</li> </ul> </td> </tr> <tr> <td colspan="2">Palmoplantar keratodermas, including pachyonychia congenita</td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">++</td> <td> <ul> <li>Mechanical treatments, such as paring and filing hyperkeratotic areas, tend to be more effective than topical medical therapy.</li> <li>Painful keratodermas, such as in pachyonychia congenita, require pain reduction techniques for many to allow continued mobility.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">+: may be considered as part of treatment (especially if tolerated); ++: favorable response to treatment; Th17: T helper type 17; IVIG: intravenous immunoglobulin; IL: interleukin; TNF: tumor necrosis factor; IgE: immunoglobulin E; NBUVB: narrowband ultraviolet B; EKC: erythrokeratodermia-cardiomyopathy; SAM: severe dermatitis, multiple allergies, and metabolic wasting.<br/>
* Typical keratolytic agents are alpha-hydroxy acids (ie, lactic, glycolic, and mandelic acids) and beta-hydroxy acids (ie, salicylic acid). Propylene glycol and urea are humectants that add moisture to skin. May be compounded with keratolytic agents to facilitate shedding.<br/>
¶ Response to biologic therapy reported.</div><div class="graphic_reference">References:
<ol>
<li>Renner ED, Hartl D, Rylaarsdam S, et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009; 124:536.</li>
<li>Small AM, Cordoro KM. Netherton Syndrome Mimicking Pustular Psoriasis: Clinical Implications and Response to Intravenous Immunoglobulin. Pediatr Dermatol 2016; 33:e222.</li>
<li>Eränkö E, Ilander M, Tuomiranta M, et al. Immune cell phenotype and functional defects in Netherton syndrome. Orphanet J Rare Dis 2018; 13:213.</li>
<li>Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab Therapy for Netherton Syndrome. JAMA Dermatol 2020; 156:907.</li>
<li>Volc S, Maier L, Gritsch A, et al. Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl. Br J Dermatol 2020; 183:165.</li>
<li>Steuer AB, Cohen DE. Treatment of Netherton Syndrome With Dupilumab. JAMA Dermatol 2020; 156:350.</li>
<li>Aktas M, Salman A, Apti Sengun O, et al. Netherton syndrome: Temporary response to dupilumab. Pediatr Dermatol 2020; 37:1210.</li>
<li>Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 2011; 131:1947.</li>
<li>Roda Â, Mendonça-Sanches M, Travassos AR, et al. Infliximab therapy for Netherton syndrome: A case report. JAAD Case Rep 2017; 3:550.</li>
<li>Yalcin AD. A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol 2016; 38:162.</li>
<li>Kaminska EC, Ortel B, Sharma V, Stein SL. Narrowband UVB phototherapy as a novel treatment for Netherton syndrome. Photodermatol Photoimmunol Photomed 2012; 28:162.</li>
<li>Maatouk I, Moutran R, Tomb R. Narrowband ultraviolet B phototherapy associated with improvement in Netherton syndrome. Clin Exp Dermatol 2012; 37:364.</li>
<li>Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol 2018; 78:498.</li>
<li>Sun Q, Wine Lee L, Hall EK, et al. Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes. Pediatr Dermatol 2021; 38:31.</li>
<li>Boyden LM, Vincent NG, Zhou J, et al. Mutations in KDSR Cause Recessive Progressive Symmetric Erythrokeratoderma. Am J Hum Genet 2017; 100:978.</li>
<li>Frommherz LH, Schempp CM, Has C. Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol 2021; 184:770.</li>
</ol></div><div id="graphicVersion">Graphic 134195 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
